Intherapeutics
2 known investors
South Korean biotech developing small-molecule ion channel drugs, led by Nav1.7 inhibitors for pain and Kv7 modulators for CNS disorders.
Also known as In Therapeutics Co. Ltd.
Investors · 2
Company profile
researched Aug 2026In Therapeutics Co. Ltd. is a South Korean drug developer founded in 2020 and based in Gyeonggi-do. It develops small-molecule and chemical drug candidates directed at ion channel targets, principally Nav1.7 (sodium channel protein type IX alpha subunit) and Kv7 potassium channels (Kv7.2 x Kv7.3 and Kv7.4). Its disclosed therapeutic focus spans nervous system diseases, immune system diseases, and endocrine and metabolic disease, with the largest concentration of programs in neurology and pain.
The pipeline includes iN1011-N17, a Nav1.7 blocker (aneratrigine) that has advanced through Phase 1 and is described as progressing to Phase 2a; DWP-17061, a Nav1.7 blocker originated by Daewoong Pharmaceutical and now listed with In Therapeutics as an active organization, at Phase 1 for chronic and arthritis pain; and preclinical assets iN1012-N17 (Nav1.7, postoperative pain), iN1213-N17 (Nav1.7, neuralgia), iN-3111-K23 (Kv7.2 x Kv7.3, epilepsy) and iN-3211-K23 (Kv7.2 x Kv7.3, Alzheimer's disease). Pipeline counts indicate roughly six discovery-stage programs, four preclinical programs and one program in Phase 1.
Traction
The company has sponsored three registered Phase 1 studies of iN1011-N17: a single-ascending-dose study in healthy volunteers registered in Australia (ACTRN12620001253998, started November 2020), a first-in-human single-ascending-dose study (NCT05496205, started September 2020, completed), and a multiple-ascending-dose Phase 1b study in healthy volunteers and post-herpetic neuralgia patients that also assesses relative bioavailability of mesylate versus hydrochloride salt capsules (NCT06218784, started November 2022, recruiting).
Latest developments
A pharmaceutics publication reported that a dry granulation manufacturing process for aneratrigine capsules resolved stability issues seen with wet granulation and supported the compound's advancement to Phase 2a. The multiple-ascending-dose Phase 1b study of iN1011-N17 in healthy volunteers and post-herpetic neuralgia patients was listed as recruiting.
▸Full profile — market position, technology, geography
Market position
In Therapeutics is an early-stage, privately held drug developer with 10-50 employees, one clinical-stage asset and the remainder of its portfolio in discovery and preclinical stages.
Technology
The company works on small-molecule modulators of voltage-gated ion channels, including selective Nav1.7 blockers and Kv7.2/Kv7.3 and Kv7.4 modulators. Formulation work on its lead Nav1.7 inhibitor aneratrigine addressed poor aqueous solubility at gastric pH (0.06 mg/mL at pH 1.2) and limited bioavailability observed in Phase 1 by using a sodium bicarbonate-containing capsule for in situ pH modulation; wet granulation at production scale caused discoloration and degradant formation, so a dry granulation process was adopted and shown to be scalable across laboratory (1.5 kg), pilot (5.4 kg) and commercial (25.9 kg) batches with total impurities below 0.05% and greater than 80% dissolution at 30 minutes at pH 4.0.
Geography
Headquartered in Gyeonggi-do, South Korea, with clinical trials registered in the United States and Australia.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsStart of NCT06218784, a three-part randomized, double-blind, placebo-controlled multiple-ascending-dose study in healthy volunteers and post-herpetic neuralgia patients, also assessing relative bioavailability of mesylate versus hydrochloride salt capsules.
Start of ACTRN12620001253998, a randomized, double-blind, placebo-controlled single-ascending-dose Phase 1 study of oral iN1011-N17 in healthy volunteers, sponsored by In Therapeutics.
In Therapeutics started NCT05496205, a randomized, double-blind, placebo-controlled single-ascending-dose Phase 1 study evaluating safety, tolerability and pharmacokinetics/pharmacodynamics of oral iN1011-N17 in healthy volunteers; the study is listed as completed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- In Therapeutics Co. Ltd. - Drug pipelines, Patents, Clinical trials - Synapsesynapse.patsnap.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Intherapeutics do?
- South Korean biotech developing small-molecule ion channel drugs, led by Nav1.7 inhibitors for pain and Kv7 modulators for CNS disorders.
- Who are Intherapeutics's investors?
- Intherapeutics's investors include Aju IB Invesment Corporation, Kiwoom Investment.